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Abstract
Background: Alternating hemiplegia of childhood is an intractable neurological disorder characterized by recurrent
episodes of alternating hemiplegia accompanied by other paroxysmal symptoms. Recent research has identified
mutations in the ATP1A3 gene as the underlying cause. Adenosine-5'-triphosphate has a vasodilatory effect, can
enhance muscle strength and physical performance, and was hypothesized to improve the symptoms of
paroxysmal hemiplegia.
Methods: A 7-year-old boy with alternating hemiplegia of childhood who was positive for a de novo ATP1A3
mutation was treated with adenosine- 5'- triphosphate supplementation orally as an innovative therapy for
2 years. Outcome was evaluated through the follow-up of improvement of hemiplegic episodes and psychomotor
development. Side effects and safety were monitored in regularity.
Results: With the dosage of adenosine-5'-triphosphate administration increased, the patient showed significantly less
frequency and shorter duration of hemiplegic episodes. Treatment with adenosine-5'-triphosphate was correlated with
a marked amelioration of alternating hemiplegia of childhood episodes, and psychomotor development has
improved. The maximum dose of oral administration of adenosine-5'-triphosphate reached 25 mg/kg per day.
Adenosine-5'-triphosphate therapy was well tolerated without complaint of discomfort and side effects.
Conclusions: The 2-year follow-up outcome of adenosine-5'-triphosphate therapy for alternating hemiplegia of
childhood was successful.
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Background
Alternating hemiplegia of childhood (AHC, MIM
104290) is a rare and intractable neurological disorder
with an early manifestation and poor prognosis. The
characteristic clinical symptom of AHC is recurrent al-
ternating episodes of hemiplegia that last from minutes
to days, and this is accompanied by other paroxysmal
symptoms including dystonia, nystagmus, autonomic
disturbances, and seizures, as well as progressive cogni-
tive and motor impairment [1, 2]. The diagnosis of
AHC was previously based on clinical manifestations,
and the most widely accepted clinical criteria to diag-
nose AHC were proposed by Bourgeois et al. In 2012,
researchers identified mutations in the ATP1A3 gene
(MIM 182350) encoding the sodium-potassium (Na+/K+)
ATPase α3 subunit as the primary genetic cause of spor-
adic AHC [3–5].
Adenosine-5'-triphosphate (ATP) is a purine nucleotide
found in every human cell, and its most important func-
tion is to transfer energy. Recent studies reported that
extracellular ATP has a vasodilatory effect and is capable
of enhancing physical performance [6]. Therefore, we
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hypothesized that ATP might ameliorate motor dysfunc-
tion in hemiplegic limbs and have a therapeutic effect in
patients with AHC.
Here we report a patient with AHC and a de novo
splice-site mutation in ATP1A3 (c.2542 + 1 G > A) who
was treated with oral ATP, which decreased the fre-
quency and severity of hemiplegic episodes.
Method
Clinical course and diagnosis
The patient was a 7-year-old boy who first presented
with recurrent hemiplegic episodes at the age of two and
a half. The extent of hemiplegia varied and he usually
experienced right-sided hemiplegia with an unsteady gait
and was prone to falling. Occasionally, he had bilateral
involvement with flaccid tetraparesis. The hemiplegic
episodes lasted several minutes and ranged from once a
week to more than 10 times per day. The first hemiple-
gic episode occurred when he was recovering from a re-
spiratory tract infection; in the following days, the
parents noted that triggering factors included hunger,
fear, fatigue, cold, agitation, and emotional stress.
This patient was born to non-consanguineous parents
after an uneventful pregnancy. There was no family his-
tory of migraine, epilepsy, or Parkinson’s disease. Neuro-
logical examinations were unremarkable when the
patient was not experiencing hemiplegic episodes. His
early speech and motor development were largely nor-
mal; he was able to say individual words at the age of
16 months and walked unaided at 18 months old. The
patient was clumsy and lacked fine motor in coordin-
ation. He had poor cognitive processing compared with
normal children his age. During the initial course of the
disease, the patient was diagnosed with epilepsy accom-
panied with Todd’s paresis in the local hospital and
treated with oxcarbazepine (0.3 g, Q12h, po), which had
no effect on the hemiplegic episodes.
The patient was first seen at the Department of
Pediatrics in Chinese PLA General Hospital at age of
3.5 years. He constantly experienced hemiplegic episodes
that generally lasted 10–20 min, with the longest lasting
about 40 min after a long journey. At their most fre-
quent, the patient experienced more than 10 attacks per
day, and this could continue for up to 2 weeks. Muscle
strength of affected limb was grade 3, and muscle ten-
sion decreased, which could not recover during inter-
racial period because of constant episodes. The patient
exhibited no pathologic reflex. Occasionally, the patient
experienced external strabismus affecting his left eye
during the attacks. This patient did not present with
dystonic spells, nystagmus, seizure, or autonomic dis-
turbance (Additional file 1: Video 1: The patients’ par-
ents provided written informed consent for releasing the
video of the patient as academic publication material).
Video-electroencephalography (EEG) revealed no simul-
taneous changes during the hemiplegic spells. There
were no metabolic abnormalities; lactic acid/pyruvic acid
exercise tests were unremarkable; and EEG, magnetic
resonance imaging, and magnetic resonance angiography
of the brain were normal. Based on the clinical manifest-
ation and work-up results, a diagnosis of AHC was con-
sidered. No tandem mass spectrometry was performed
and no mitochondrial and/or genetic testing was done.
Oxcarbazepine was stopped, and flunarizine (5 mg/day)
was administered for 1 year, but had no obvious effect
on attack frequency or duration, therefore was stopped.
Coenzyme Q10 (10 mg, Q12h, po) and carnitine (1 g,
once a day) were then prescribed together, but no bene-
ficial effects were observed. Carnation was stopped be-
cause of its expensive.
When the patient was 5 years and 10 months, a gen-
etic diagnosis of AHC due to ATP1A3 mutation was
confirmed. Specifically, the patient was determined to
possess a de novo splice-site mutation (c.2542 + 1 G > A)
in intone 18 of the ATP1A3 gene that was not present in
his parents or elder brother (Fig. 1).
ATP treatment
This research was approved by the ethics committees of
Chinese PLA General Hospital, and the patient’s parents
provided informed consent. Adenosine triphosphate dis-
odium reagent was produced by Guangzhou Baiyunshan
Guanghua Pharmaceutical Co. Ltd. At age of 6 years,
ATP was orally administered at an initial dosage of
2 mg/day.d. When the hemiplegic episodes were aggra-
vated, ATP was intravenously administered at 40 mg/day
for 10 days. His parents were asked to record paroxys-
mal symptoms and side effects in detail, and blood
counts and liver and renal function were regularly moni-
tored every 3 months. His psychomotor development
was also clinically assessed. Because of the worry from
parents, he also continued taking coenzyme Q10 (10 mg
twice a day) in the first year of treatment.
Results
The ATP and coenzyme Q10 dosages were 20 mg twice
a day (2 mg/kg/day), and 10 mg twice a day, respectively.
The patient experienced fewer hemiplegic attacks that
were shorter than those experienced before initiating
ATP. When hemiplegic spells were evoked by a respira-
tory tract infection or fatigue, the symptoms would re-
mit 2–3 days after intravenous ATP administration.
The dosage of ATP was gradually increased to 100 mg
three times a day (15 mg/kg/day), and the patient expe-
rienced a marked reduction in the number of attacks, in-
cluding a month without an event. Intravenous ATP
administration was no longer needed even if physical or
emotional triggers were present.
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When titrating the dosage of ATP to 160 mg three
times a day (24 mg/kg/day), the patient got mild hemi-
plegia of the right limbs lasted for several minutes only
three times over 2 months, and the paroxysms were con-
sistently provoked by crying and overtiredness. Despite
this, the episodes were much less severe (Fig. 2). The
neurological physical examination shows muscle
strength of affected limb was grade 4, and muscle ten-
sion decreased in the stage of attack, while no abnormal
physical signs were observed in interphase.
After the patient’s hemiplegic episodes were markedly
reduced, the patient showed noticeable improvements in
balance and fine motor coordination. He was able to run
without falling over (Additional file 2: Video 2), and his
academic performance improved including basic math-
ematical skills such as addition and subtraction and
reciting nursery rhymes. Despite these improvements,
his memory and perception abilities were delayed.
With the satisfactory result accompanied of titrating
the dosage of ATP, the parent was tried to discontinue
coenzyme Q10 after treatment for 1 year. As a result,
there was no significant change in the frequency and se-
verity of attacks after ATP monotherapy.
At present, we have followed up for 2 years. The max-
imum dose of oral ATP alone has increased to 240 mg
three times a day (25 mg/kg/day). There was still a
hemiplegic episode every several days. We did not in-
crease the dosage based on the acceptable effects from
parents. Most particularly, every dose increase acquired
attack-free for about ten days.
After administered with ATP orally for 2 years, the pa-
tient was tolerated well with no nausea, vomiting,
Fig. 1 Chromatograms of the de novo ATP1A3 mutation. Data were obtained by Sanger sequencing during the confirmation process. The black
square represents the proband. Black solid lines indicate exonic nucleotide sequences, and blue dotted lines indicate intronic nucleotide sequences.
A mutation (c.2542 + 1 G > A) in intron 18 was identified in this patient
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abdominal pain, or gastrointestinal discomfort. No com-
plaints of adverse events happened. The patient’s liver
parameters (glutamic-pyruvic transaminase, glutamic-
oxalacetic transaminase), kidney parameters (including
urea, creatinine, uric acid), blood albumin, bilirubin,
electrolytes (sodium, potassium, calcium, magnesium)
were monitored every half a year and within normal
limits, except serum uric acid occasionally reached
slightly higher than the upper limit, which indicated that
prolonged ATP administration was safe.
Discussion
Since AHC was first described, various drugs have been
administered to reduce symptoms, but none has been
particularly effective. Flunarizine is the first-line treat-
ment, and several studies have reported that it reduces
the severity, duration, and frequency of hemiplegic spells
[7]. However; it has proven ineffective in a considerable
number of patients, underscoring the need for effective
therapies to treat AHC.
Here we report the case of AHC in a patient who had
a previously reported [4, 8] de novo splice-site mutation
in ATP1A3 (c.2542 + 1 G > A). This mutation was rare in
previous report and detected in only one patient with in-
tellectual disability, walking problem, dystonia, hemiple-
gic attack, and epilepsy. The patient in our study
presented a similar phenotype except epilepsy. The lar-
ger number of patient with same genotype were needed
to define the clinical profiles.
In this case, we found patient showed a dramatic re-
duction in hemiplegic episodes and noticeable improve-
ments in motor ability with initiation of oral ATP
therapy. This treatment was well tolerated with no ad-
verse effects in 2 years. There were notable reductions in
the frequency, duration, and extent of hemiplegic
episodes. A temporal correlation between treatment and
therapeutic effects was observed; moreover, the patient’s
symptoms seemed to improve in a dose-dependent fash-
ion. This case suggests that ATP might be an effective
medication for AHC treatment.
The ATP1A3 gene encodes the α3-subunit of the
sodium-potassium (Na+/K+) ATPase, which is well
known as transmembrane ion pumps generating chem-
ical and electrical gradients of Na+ and K+ across the
membrane. The gradients have a key role in cellular
physiological functions, including electrical excitability
of nerves and muscles. The ATP1A3 mutations would
result in abnormal protein expression of Na+/K+
ATPase. Moreover, ATP, serving as a direct source of en-
ergy in living cell, provides energy for the ATPase. Sup-
plementation of ATP may improve the dysfunction of
Na+/K+ ATPase to alleviate symptoms. However, func-
tional studies of ATPase and genotype-phenotype corre-
lations of ATP1A3 mutations should be further
investigated [8].
Extracellular ATP can influence neurotransmission,
muscle contraction, cardiac function, platelet function,
vasodilatation, muscle oxygenation, and liver glycogen
metabolism. ATP has been used as an adjuvant therapy
for progressive muscle atrophy, supraventricular tachy-
cardia, cerebral hemorrhage, cardiac insufficiency, myo-
cardial diseases, paroxysmal atrial tachycardia, and
hepatitis [6]. A recent randomized, double-blind, con-
trolled study confirmed that oral supplementation with
ATP (120 mg three times a day) increased quadriceps
strength and benefitted patients recovering from total
knee arthroplasty [9]. Another group reported that oral
ATP administered as a disodium salt increased blood
flow in exercising animals and humans, which could im-
prove oxygen and nutrient delivery to the muscle and
Fig. 2 Daily frequency of alternating hemiplegia episodes at different ATP dosages. The numbers of hemiplegic episodes at different ATP administration
are noted. As the ATP dosage increased, the patient experienced markedly fewer hemiplegic episodes
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accelerate the removal of metabolic waste products such
as lactate and urea. [10] Therefore, ATP might increase
muscle strength in hemiplegic limbs via vasodilatation
and increased blood flow.
There are limited data describing ATP dosages, espe-
cially in pediatric patients. Oral ATP at a maximum
daily dose of 5000 mg was given to healthy adults for
28 days, and the findings of that study suggested that
chronic ATP administration is safe with regard to liver
and kidney parameters [11]. In this case, the maximum
dosage was 480 mg/day, and the patient did not com-
plain of discomfort and manifested no complications.
There are few studies regarding therapy for AHC. Al-
though we only treated a single case, this patient showed
a significant response to ATP, indicating that its use in
AHC is worth exploring. Further large-scale studies in-
volving patients with confirmed AHC are needed to de-
finitively determine optimum dosing regimens and
confirm its efficacy.
Conclusions
The 1-year follow-up outcome of adenosine-5'-triphos-
phate therapy for alternating hemiplegia of childhood
was successful.
Additional files
Additional file 1: Video 1. This video was recorded in June 2011, at
that time the patient was at age of 3.5 years and first seen at the
Department of Pediatrics in Chinese PLA General Hospital. He frequently
experienced right-sided hemiplegia with an unsteady gait and was prone
to falling. (MOV 18913 kb)
Additional file 2: Video 2. This video was recorded in December 2014.
After treatment of ATP, this patient’s hemiplegic episodes were markedly
reduced, the patient showed noticeable improvements in balance and
fine motor coordination. (MOV 71448 kb)
Abbreviation
AHC: alternating hemiplegia of childhood; ATP: adenosine-5'-triphosphate;
EEG: electroencephalography.
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